Abstract
Purpose
The survival of patients with hepatocellular carcinoma (HCC) has been prolonged with improvements in various diagnostic tools and treatment modalities. Consequently, bone metastases from HCC are diagnosed more frequently. We investigated the clinical features, prognosis, treatment outcomes, and prognostic factors of HCC presenting with bone metastasis.
Methods
Between June 2000 and April 2007, we recruited 37 consecutive HCC patients presenting with bone metastasis. These patients were divided into an untreated control group (n = 16) and a treated group (n = 21).
Results
The mean age of the patients was 61.1 years (male:female, 31:6). The most common cause of HCC was hepatitis B virus infection (56.8%). Twenty-two patients (59.5%) were of Child-Pugh class A and 15 (40.5%) were of Child-Pugh class B. Spinal metastasis was most common and noted in 21 patients (56.7%). The treatment modalities in the treated group included intra-arterial chemotherapy in nine patients (42.8%), systemic chemotherapy in five (23.8%), and both intra-arterial and systemic chemotherapy in seven (33.4%). The median survival of all patients was 6.2 months (range 0.7–46.6); that of untreated control group and the treated group was 2.9 (range 0.7–42.2) and 9.7 (range 0.9–46.6) months, respectively, with no significant difference (log-rank test, P = 0.081). Cox regression analysis revealed that the presence of ascites at the initial presentation was the only prognostic factor (P = 0.016).
Conclusion
Although our study showed that locoregional and/or systemic chemotherapy did not provide significant survival prolongation compared to supportive care in patients with HCC initially accompanied by bone metastasis, a more large-scaled randomized study might be required.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahn SH, Han K-H, Park JY et al (2004) Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM Stage IVa). Yonsei Med J 45:847–858
Anonymous (2000) Liver Cancer Study Group of Japan: stage. In: Makuuchi M (ed) The general rules for the clinical and pathological study of primary liver cancer (in Japanese), 4th edn. Kanehara and Co., Ltd, Tokyo, p 19
Bruix J, Sherman M, Llovet JM et al (2001) EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 35:421–430
Castellano L, Calandra M, Del Vecchio Blanco C, De Sio I (1997) Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. J Hepatol 27:862–870
El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823
Fukutomi M, Yokota M, Chuman H et al (2001) Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 13:1083–1088
Iguchi H, Yokota M, Fukutomi M et al (2002) A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 21:309–313
Kuhlman JE, Fishman EK, Leichner PK, Magid D, Order SE, Siegelman SS (1986) Skeletal metastases from hepatoma: frequency, distribution, and radiographic features. Radiology 160:175–178
Liaw CC, Ng KT, Chen TJ, Liaw YF (1989) Hepatocellular carcinoma presenting as bone metastasis. Cancer 64:1753–1757
Moore KP, Wong F, Gines P et al (2003) The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38:258–266
Muldoon CJ (1974) A hepatocarcinoma with osseous metastases. J Laryngol Otol 88:891–892
Nakashima T, Okuda K, Kojiro M et al (1983) Pathology of hepatocellular carcinoma in Japan: 232 consecutive cases autopsied in 10 years. Cancer 51:863–877
Natsuizaka M, Omura T, Akaike T et al (2005) Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20:1781–1787
Okazaki N, Yoshino M, Yoshida T, Hirohashi S, Kishi K, Shimosato Y (1985) Bone metastasis in hepatocellular carcinoma. Cancer 55:1991–1994
Reichbach EJ, Levinson JD, Fagin RR (1970) Unusual osseous metastases of hepatoma. JAMA 213:2078–2079
Segawa T, Tsuchiya R, Furui J, Izawa K, Tsunoda T, Kanematsu T (1993) Operative results in 143 patients with hepatocellular carcinoma. World J Surg 17:663–667
Seong J, Koom WS, Park HC (2005) Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 25:261–265
Simonetti RG, Camma C, Fiorello F, Politi F, D’Amico G, Pagliaro L (1991) Hepatocellular carcinoma: a worldwide problem and the major risk factors. Dig Dis Sci 36:962–972
Talerman A, Magyar E (1973) Hepatocellular carcinoma presenting with pathologic fracture due to bone metastases. Cancer 32:1477–1481
Vigneul JC, Nouel O, Klap P, Al Helali M (1982) Metastatic hepatocellular carcinoma of the mandible. J Oral Maxillofac Surg 40:745–749
Wands JR, Blum HE (1991) Primary hepatocellular carcinoma. N Engl J Med 325:729–731
Zubler MA, Rivera R, Lane M (1981) Hepatoma presenting as a retro-orbital metastasis. Cancer 48:1883–1885
Acknowledgments
This study was supported by the grant of the Good Health R&D Project from the Ministry of Health and Welfare, Republic of Korea (A050021), and in part by the grant from Brain Korea 21 Project for Medical Science. The author thanks Mooyoung Han, Ph.D. (Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea) for critical comments on statistics.
Author information
Authors and Affiliations
Corresponding author
Additional information
S. U. Kim and D. Y. Kim have equally contributed to this work.
Rights and permissions
About this article
Cite this article
Kim, S.U., Kim, D.Y., Park, J.Y. et al. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol 134, 1377–1384 (2008). https://doi.org/10.1007/s00432-008-0410-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-008-0410-6